- Home
- TFPM vs ACAD Comparison
TFPM vs ACAD Comparison
Compare TFPM & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TFPM
- ACAD
- Stock Information
- Founded
- TFPM 2016
- ACAD 1993
- Country
- TFPM Canada
- ACAD United States
- Employees
- TFPM N/A
- ACAD N/A
- Industry
- TFPM Precious Metals
- ACAD Biotechnology: Pharmaceutical Preparations
- Sector
- TFPM Industrials
- ACAD Health Care
- Exchange
- TFPM Nasdaq
- ACAD Nasdaq
- Market Cap
- TFPM 3.3B
- ACAD 2.8B
- IPO Year
- TFPM N/A
- ACAD 2004
- Fundamental
- Price
- TFPM $16.09
- ACAD $17.89
- Analyst Decision
- TFPM Strong Buy
- ACAD Buy
- Analyst Count
- TFPM 4
- ACAD 19
- Target Price
- TFPM $20.50
- ACAD $26.17
- AVG Volume (30 Days)
- TFPM 318.0K
- ACAD 4.2M
- Earning Date
- TFPM 01-01-0001
- ACAD 02-25-2025
- Dividend Yield
- TFPM 1.00%
- ACAD N/A
- EPS Growth
- TFPM N/A
- ACAD N/A
- EPS
- TFPM N/A
- ACAD 0.78
- Revenue
- TFPM $246,517,000.00
- ACAD $929,236,000.00
- Revenue This Year
- TFPM $34.53
- ACAD $36.78
- Revenue Next Year
- TFPM $11.05
- ACAD $8.19
- P/E Ratio
- TFPM N/A
- ACAD $23.02
- Revenue Growth
- TFPM 25.66
- ACAD 47.06
- 52 Week Low
- TFPM $11.75
- ACAD $14.15
- 52 Week High
- TFPM $18.88
- ACAD $29.29
- Technical
- Relative Strength Index (RSI)
- TFPM 59.38
- ACAD 54.79
- Support Level
- TFPM $15.50
- ACAD $16.61
- Resistance Level
- TFPM $15.91
- ACAD $18.23
- Average True Range (ATR)
- TFPM 0.35
- ACAD 0.72
- MACD
- TFPM 0.13
- ACAD -0.02
- Stochastic Oscillator
- TFPM 94.61
- ACAD 47.74
About TFPM Triple Flag Precious Metals Corp.
Triple Flag Precious Metals Corp is a precious-metals-focused streaming and royalty company. Its revenues are largely generated from a diversified portfolio of properties in Australia, Canada, Colombia, Cote d'Ivoire, Honduras, Mexico, Mongolia, Peru, South Africa, and the United States.
About ACAD ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecules drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.